

Resource Summary Report

Generated by T1D on Jul 31, 2026

Essen: IncuCyte ZOOM System

RRID:SCR_019874

Type: Tool

Proper Citation

Essen: IncuCyte ZOOM System (RRID:SCR_019874)

Resource Information

URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_019874.pdf

Proper Citation: Essen: IncuCyte ZOOM System (RRID:SCR_019874)

Description: IncuCyte ZOOM system is a live-cell imaging and analysis platform that enables automated quantification of cell behavior over time (from hours to weeks) by automatically gathering and analyzing images around the clock. The system provides insight into active biological processes in real-time which is not possible using single-point and end-point measurements. The system resides within the controlled environment of a standard cell incubator. All imaging is completely non-invasive and non-perturbing to cell health. The system can process multiple plates, flasks and dishes in parallel and does not depend on shuttling plates into and out of the incubator.

Resource Type: instrument resource

Keywords: Essen, Long-Term Cellular Assay, Instrument Equipment,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_019874.pdf

Resource Name: Essen: IncuCyte ZOOM System

Resource ID: SCR_019874

Alternate IDs: Model_Number_Incucyte

Old URLs: https://www.essenbioscience.com/media/uploads/files/8000-0333-E00-IncuCyte_ZOOM_brochure.pdf

Record Creation Time: 20220129T080347+0000

Record Last Update: 20260725T190919+0000

Ratings and Alerts

No rating or validation information has been found for Essen: IncuCyte ZOOM System.

No alerts have been found for Essen: IncuCyte ZOOM System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 40 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Conti BA, et al. (2025) N6-methyladenosine in DNA promotes genome stability. *eLife*, 13.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. *Cancer research*, 85(18), 3503.

Chenoweth AM, et al. (2025) An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. *Cancer research*, 85(22), 4521.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1333.

Wang Q, et al. (2025) Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss. *Cancer research communications*, 5(6), 994.

Zelic M, et al. (2025) Single-cell transcriptomic and functional studies identify glial state changes and a role for inflammatory RIPK1 signaling in ALS pathogenesis. *Immunity*, 58(4), 961.

Kok N, et al. (2025) CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. *iScience*, 28(6), 112548.

Febres-Aldana CA, et al. (2025) Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. *Cancer discovery*, 15(6), 1141.

Fang P, et al. (2025) Differential control of growth and identity by HNF4 α isoforms in pancreatic ductal adenocarcinoma. *Molecular cancer research : MCR*.

Bancet A, et al. (2024) Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric γ D pocket. *iScience*, 27(2), 108903.

Holota R, et al. (2024) Cleaved caspase-3 is present in the majority of glial cells in the intact rat spinal cord during postnatal life. *Histochemistry and cell biology*, 161(3), 269.

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. *Molecular cancer therapeutics*, 23(10), 1494.

Long D, et al. (2024) Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma. *Cell reports. Medicine*, 5(9), 101699.

Griesinger AM, et al. (2024) Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(8), 1544.

Lin LL, et al. (2024) PAI-1 uncouples integrin- α 1 from restrain by membrane-bound β -catenin to promote collagen fibril remodeling in obesity-related neoplasms. *Cell reports*, 43(8), 114527.

Imai T, et al. (2024) The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. *Immunity*, 57(7), 1497.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. *Cancer cell*, 42(10), 1676.

Zhang K, et al. (2024) A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer. *Cell chemical biology*, 31(11), 1942.

Pascual-Pasto G, et al. (2024) Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3578.